Glaucoma News and Research

Latest Glaucoma News and Research

UCL scientists: Simple eye test can help detect and diagnose major neurological diseases

A simple and inexpensive eye test could aid detection and diagnosis of major neurological diseases such as Alzheimer's at an earlier stage than is currently possible, according to new research by UCL scientists.

18 Jan 2010

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

Medical Marijuana Inc applauds the New Jersey State Assembly and Senate for having approved "The New Jersey Compassionate Use Medical Marijuana Act" on Monday, January 11, 2010. A804/S119 removes state-wide penalties for possession of up to two ounces of marijuana when a New Jersey licensed Physician recommends it for one of the qualified medical conditions including Aids, Cancer, Multiple Sclerosis and Crohn's disease among others.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the working of the heart.

11 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

Medical Marijuana launches National Educational Expo at the Los Angeles Convention Center

Medical Marijuana Inc is proud to announce the launch of its first National Educational Expo at the Los Angeles Convention Center, Theatre Room on January 16 & 17, 2010.

5 Jan 2010

Steroids not superior to laser treatments for DME

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

27 Dec 2009

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

Routinely used to treat patients for heart attack or high blood pressure, beta blockers are known for their role in helping to protect the heart. A new study in the January issue of the journal Anesthesiology looks at the effects of beta blockers on surgical outcomes, revealing that the cardioprotective effects of the medication could be compromised by acute surgical anemia.

23 Dec 2009

Medical Marijuana announces the Nationwide Launch of its Educational Seminar series

Medical Marijuana, Inc. endorsed today the unprecedented act of President Obama signing into federal law the removal of restrictions on the use of medical marijuana in the nation's capitol, which underscores MJNA's foresight in becoming the first US public company to emerge, providing solutions to this revolutionary growth industry.

21 Dec 2009

Diabetes patients at higher risk from glaucoma

An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.

19 Dec 2009

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals, Inc., today announced the Company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

18 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced on December 13 the initiation of the regulatory process for a Glaucoma Phase II clinical study in Israel. Leading Medical Centers in Israel will enroll 44 patients with Ocular Hypertension or Glaucoma for the first segment of the trial, who will be treated for 16 weeks with CF101 or placebo.

15 Dec 2009

Alcon signs definitive agreement to acquire Optonol

Alcon announced today that it has entered into a definitive agreement to acquire Optonol, Ltd., a medical device company that develops, manufactures and markets novel miniature surgical implants used to lower intraocular pressure (IOP) in patients with glaucoma.

14 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

HESG to acquire stake in two Montana-based marijuana companies

Health Sciences Group, Inc. would like to announce that it is in strong negotiations to acquire a minority stake in two separate Montana-based marijuana growing, distribution and care giving operations.

5 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Glaucoma News and Research

Latest Glaucoma News and Research

UCL scientists: Simple eye test can help detect and diagnose major neurological diseases

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Medical Marijuana launches National Educational Expo at the Los Angeles Convention Center

Steroids not superior to laser treatments for DME

Beta blockers may increase risk of anemia-induced adverse cardiovascular events

Medical Marijuana announces the Nationwide Launch of its Educational Seminar series

Diabetes patients at higher risk from glaucoma

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Alcon signs definitive agreement to acquire Optonol

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

HESG to acquire stake in two Montana-based marijuana companies

Patients new to chronic disease medication face risk of medication discontinuation, finds study

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Eli Lilly's Cymbalta receives FDA approval

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Glaucoma News and Research

Latest Glaucoma News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in